Was it worth it? Patients’ perspectives on the perceived value of genomic-based individualized medicine

Journal of Community Genetics

Volumn 7, Issue 2, 2016, Pages 145-152

  Halverson, Colin ME ^a,b   Clift, Kristin E ^a,c   McCormick, Jennifer B ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c MAYO CLINIC   (United States)

Author keywords

Clinical utility; Genomic sequencing; Patient views; Precision medicine

Indexed keywords

ADULT; AGED; ALTRUISM; ARTICLE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; GENE MUTATION; GENE SEQUENCE; GENETIC IDENTIFICATION; GENOMICS; HUMAN; INFORMED CONSENT; MALE; MALIGNANT NEOPLASTIC DISEASE; MEDICAL RESEARCH; ONCOLOGY; PATIENT ADVOCACY; PATIENT ATTITUDE; PATIENT DECISION MAKING; PERSONALIZED MEDICINE; PRIORITY JOURNAL; RARE DISEASE; SEMI STRUCTURED INTERVIEW;

EID: 84957695802     PISSN: 1868310X     EISSN: 18686001     Source Type: Journal    
DOI: 10.1007/s12687-016-0260-x     Document Type: Article

References (45)

1. Bennette CS, Trinidad SB, Fullerton S, Patrick D, Amendola L, Burke W, Hisama F, Jarvik G, Regier D, Veenstra D (2013) Return of incidental findings in genomic medicine: measuring what patients value—development of an instrument to measure preferences for information from next-generation testing (IMPRINT). Genet Med 15:873–881
2. Berg JS, Khoury MJ, Evans JP (2011) Deploying whole genome sequencing in clinical practice and public health: meeting the challenge one bin at a time. Genet Med 13(6):499–504. doi:10.1097/GIM.0b013e318220aaba
3. Beskow Laura M, Wylie B (2010) “Offering individual genetic research results: context matters.”. Sci Transl Med 2(38):38c20
4. Beskow LM, Grady C, Iltis AS, Sadler JZ, Wilfond BS (2009) Points to consider: the research ethics consultation service and the IRB. IRB 31(6):1–9
5. Biesecker LG, Green RC (2014) Diagnostic clinical genome and exome sequencing. N Engl J Med 370(25):2418–25. doi:10.1056/NEJMra1312543
6. Bollinger JM, Green RC, Kaufman D (2013) Attitudes about regulation among direct-to-consumer genetic testing customers. Genet Test Mol Biomarkers 17(5):424–28. doi:10.1089/gtmb.2012.0453
7. Botkin Jeffrey R, Steven Teutsch M, Celia Kaye I, Maxine H, James Haddow E, Linda Bradley A, Kathleen Szegda W, David D, EGAPP Working Group (2010) Outcomes of interest in evidence-based evaluations of genetic tests. Genet Med Off J Am Coll Med Genet 12(4):228–35. doi:10.1097/GIM.0b013e3181cdde04
8. Britten N (1995) Qualitative research: qualitative interviews in medical research. BMJ 311(6999):251–53. doi:10.1136/bmj.311.6999.251
9. Bunnik, Eline M., A. Cecile J. W. Janssens, and Maartje H. N. Schermer. 2014. “Personal utility in genomic testing: is there such a thing?” Journal of Medical Ethics, May, medethics – 2013–101887. doi:10.1136/medethics-2013-101887
10. Chakradhar S (2015) Insurance companies are slow to cover next-generation sequencing. Nat Med 21(3):204–5. doi:10.1038/nm0315-204
11. Clift, Kristin E., Colin M. E. Halverson, Alexander S. Fiksdal, Ashok Kumbamu, Richard R. Sharp, and Jennifer B. McCormick. 2015. “Patients’ views on incidental findings from clinical exome sequencing.” Applied & Translational Genomics 4 (March): 38–43. doi:10.1016/j.atg.2015.02.005
12. Conti R, Veenstra DL, Armstrong K, Lesko LJ, Grosse SD (2010) Personalized medicine and genomics: challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities. Med Decis Mak Int J Soc Med Decis Mak 30(3):328–40. doi:10.1177/0272989X09347014
13. Corbin J, Strauss A (2007) Basics of Qualitative Research: Techniques and Procedures for Developing Grounded Theory, 3rd edn. SAGE Publications, Inc., Los Angeles, California
14. Davies CA (2007) Reflexive Ethnography: A Guide to Researching Selves and Others. New York: Routledge.
15. De Ligt, Joep, Marjolein H. Willemsen, Bregje W.M. van Bon, Tjitske Kleefstra, Helger G. Yntema, Thessa Kroes, Anneke T. Vulto-van Silfhout, et al. 2012. “Diagnostic exome sequencing in persons with severe intellectual disability.” New England Journal of Medicine 367 (20): 1921–29. doi:10.1056/NEJMoa1206524
16. Foster Morris W, John Mulvihill J, Richard Sharp R (2009) Evaluating the utility of personal genomic information. Genet Med Off J Am Coll Med Genet 11(8):570–74. doi:10.1097/GIM.0b013e3181a2743e
17. Graves KD, Sinicrope PS, McCormick JB, Zhou Y, Vadaparampil ST, Lindor NM (2015) Public perceptions of disease severity but not actionability correlate with interest in receiving genomic results: nonalignment with current trends in practice. Public Health Genomics 18(3):173–83. doi:10.1159/000375479
18. Green RC, Berg JS, Grody WW, Kalia SS, Korf BR, Martin CL, Amy McGuire L (2013) ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med Off J Am Coll Med Genet 15(7):565–74. doi:10.1038/gim.2013.73
19. Grosse SD, Kalman L, Khoury MJ (2010) Evaluation of the validity and utility of genetic testing for rare diseases. Adv Exp Med Biol 686:115–31. doi:10.1007/978-90-481-9485-8_8
20. Grosse, Scott D., and Muin J. Khoury. 2006. “What is the clinical utility of genetic testing?” Genetics in Medicine: Official Journal of the American College of Medical Genetics 8 (7): 448–50. doi:10.109701.gim.0000227935.26763.c6
21. Grosse SD, McBride CM, Evans JP, Khoury MJ (2009) Personal utility and genomic information: look before you leap. Genet Med Off J Am Coll Med Genet 11(8):575–76. doi:10.1097/GIM.0b013e3181af0a80
22. Hunter J, Corcoran K, Leeder S, Phelps K (2012) Appealing to altruism is not enough: motivators for participating in health services research. J Empir Res Hum Res Ethics: JERHRE 7(3):84–90. doi:10.1525/jer.2012.7.3.84
23. Jacob Howard J, Kelly A, David Bick P, Kent B, David Dimmock P, Michael F, Jennifer G et al (2013) Genomics in clinical practice: lessons from the front lines. Sci Transl Med 5(194):194cm5. doi:10.1126/scitranslmed.3006468
24. Jarvik GP, Amendola LM, Berg JS, Brothers K, Clayton EW, Chung W, Barbara Evans J et al (2014) Return of genomic results to research participants: the floor, the ceiling, and the choices in between. Am J Hum Genet 94(6):818–26. doi:10.1016/j.ajhg.2014.04.009
25. Kaufman DJ, Bollinger JM, Dvoskin RL, Scott JA (2012) Risky business: risk perception and the use of medical services among customers of DTC personal genetic testing. J Genet Couns 21(3):413–22. doi:10.1007/s10897-012-9483-0
26. Kleinman A (1988) The illness narratives: suffering, healing & the human condition. Basic Books, New York
27. Kopits IM, Chen C, Roberts JS, Uhlmann W, Green RC (2011) Willingness to pay for genetic testing for Alzheimer's disease: a measure of personal utility. Genet Test Mol Biomarker 15(12):871–875
28. Lazaridis KN, McAllister TM, Babovic-Vuksanovic D, Beck SA, Borad MJ, Bryce AH, Asher Chanan-Khan A et al (2014) Implementing individualized medicine into the medical practice. Am J Med Genet Part C, Seminar Med Genet 166(1):15–23. doi:10.1002/ajmg.c.31387
29. Lindor NM, Johnson KJ, McCormick JB, Klee EW, Ferber MJ, Farrugia G (2013) Preserving personal autonomy in a genomic testing era. Genet Med Off J Am Coll Med Genet 15(5):408–9. doi:10.1038/gim.2013.24
30. Mein G, Seale C, Rice H, Johal S, Ashcroft RE, Ellison G, Tinker A (2012) Altruism and participation in longitudinal health research? Insights from the Whitehall II Study. Soc Sci Med (1982) 75(12):2345–52. doi:10.1016/j.socscimed.2012.09.006
31. Middleton, Anna, Caroline F. Wright, Katherine I. Morley, Eugene Bragin, Helen V. Firth, Matthew E. Hurles, and Michael Parker. 2015. “Potential research participants support the return of raw sequence data.” Journal of Medical Genetics, May, jmedgenet – 2015–103119. doi:10.1136/jmedgenet-2015-103119
32. Miyatake S, Matsumoto N (2014) Genetics: clinical exome sequencing in neurology practice. Nat Rev Neurol 10(12):676–78. doi:10.1038/nrneurol.2014.213
33. Ormond KE, Wheeler MT, Hudgins L, Klein TE, Butte AJ, Altman RB, Ashley EA, Greely HT (2010) Challenges in the clinical application of whole-genome sequencing. Lancet 375(9727):1749–51. doi:10.1016/S0140-6736(10)60599-5
34. Payne K, Annemans L (2013) Reflections on market access for personalized medicine: recommendations for Europe. Value Health 16:S32–S38
35. Porter ME (2010) What is value in health care? N Engl J Med 363(26):2477–81. doi:10.1056/NEJMp1011024
36. Ravitsky V, Wilfond BS (2006) Disclosing individual genetic results to research participants. Am J Bioethics: AJOB 6(6):8–17. doi:10.1080/15265160600934772
37. Roberts JS, Uhlmann WR (2013) Genetic susceptibility testing for neurodegenerative diseases: ethical and practice issues. Prog Neurobiol 110:89–101
38. Rogowski WH, Grosse SD, Khoury MJ (2009) Challenges of translating genetic tests into clinical and public health practice. Nat Rev Genet 10(7):489–95. doi:10.1038/nrg2606
39. Sanderson SC, Diefenbach MA, Zinberg R, Horowitz CR, Smirnoff M, Zweig M, Streicher S, Jabs EW, Richardson LD (2013) Willingness to participate in genomics research and desire for personal results among underrepresented minority patients: a structured interview study. Journal of Community Genetics 4(4):469–82. doi:10.1007/s12687-013-0154-0
40. Sanderson S, Zimmern R, Kroese M, Higgins J, Patch C, Emery J (2005) How can the evaluation of genetic tests be enhanced? Lessons learned from the ACCE framework and evaluating genetic tests in the United Kingdom. Genet Med 7(7):495–500. doi:10.1097/01.gim.0000179941.44494.73
41. Taylor, Jenny C., Hilary C. Martin, Stefano Lise, John Broxholme, Jean-Baptiste Cazier, Andy Rimmer, Alexander Kanapin, et al. 2015. “Factors influencing success of clinical genome sequencing across a broad spectrum of disorders.” Nature Genetics advance online publication (May). doi:10.1038/ng.3304
42. Veenstra DL, Piper M, Haddow JE, Pauker SG, Klein R, Richards CS, Sean Tunis R et al (2013) Improving the efficiency and relevance of evidence-based recommendations in the era of whole-genome sequencing: an EGAPP methods update. Genet Med Off J Am Coll Med Genet 15(1):14–24. doi:10.1038/gim.2012.106
43. Wasson K, Hogan NS, Sanders TN, Helzlsouer KJ (2012) Primary care patients’ views, attitudes, and decision-making factors regarding direct-to-consumer personal genome testing: results from a qualitative study. AJOB Prim Res 3(2):24–35. doi:10.1080/21507716.2011.650344
44. Yang Y, Muzny DM, Xia F et al (2014) Molecular findings among patients referred for clinical whole-exome sequencing. JAMA 312(18):1870–79. doi:10.1001/jama.2014.14601
45. Yu J-H, Harrell TM, Jamal SM, Tabor HK, Bamshad MJ (2014) Attitudes of genetics professionals toward the return of incidental results from exome and whole-genome sequencing. Am J Hum Genet 95(1):77–84. doi:10.1016/j.ajhg.2014.06.004